ABM joining international work on SARS-CoV-2 vaccine
19:22
In response to the current epidemiological threat caused by the appearance of the SARS-CoV-2 virus, the President of the Medical Research Agency (ABM), decided to start ABM's own study entitled "Research on a vaccine against the SARS-CoV-2 virus and support for research into the search for effective therapy, which will be implemented in partnership with Polish and international centers.
Talks are currently taking place regarding the shape and possibilities of cooperation, among others, with the American National Institutes of Health (NIH) and dr. Anthony S. Fauci, Director of the Institute of Infectious Diseases in Washington. ABM also conducts advanced talks with international universities in Europe, and the Chinese Embassy, as well as researchers from Germany and Canada.
One of the concepts prepared as part of the project is the proposal implemented by the National Institute of Oncology and the Institute of Biochemistry and Biophysics PAS, which in cooperation with other scientists, it plans to use an innovative technology combining the use of bacteriophages and nanoproteins to develop therapy against SARS-CoV-2 virus infection.
“In our project, we want to use a nanoprotein that will be placed on the bacteriophage head. This nano-antibody will be able to recognize the SARS-CoV-2 virus and prevent it from entering human cells. Until now, no one has used the bacteriophage-nanoprotein combination to fight human viruses. We are pioneers,” prof. Jan Walewski, the project leader and the director of the National Institute of Oncology and the Institute of Biochemistry and Biophysics of PAN.
(WBJ)
